What therapeutic effect does pramlintide provide related to gastric function?

Pramlintide, an amylin analog, is used as an adjunct treatment for diabetes and has a significant impact on gastric function, specifically by delaying gastric emptying. This therapeutic effect is beneficial as it helps to moderate postprandial (after meal) blood glucose spikes. By slowing the rate at which food moves from the stomach to the small intestine, pramlintide allows for a more gradual absorption of glucose into the bloodstream, aiding in overall glycemic control.

In contrast, other options suggest actions not associated with pramlintide. For example, stimulating glucagon secretion is primarily a function of other hormones and counterregulatory mechanisms, while pramlintide actually has the opposite effect of reducing glucagon secretion in response to meals. Decreasing insulin sensitivity is not an action of pramlintide; its role is supportive, helping to enhance the effects of insulin, rather than impairing them. Lastly, pramlintide does not increase glucose absorption; rather, it helps to regulate the timing and effectiveness of glucose absorption through its effect on gastric emptying.

By delaying gastric emptying, pramlintide aligns with the objective of achieving better post-meal glucose control in individuals with diabetes.